Data on Rosetta Genomics’ Novel Thyroid Nodule Classification Assay to be Presented at the American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces that data on the Company’s novel, microRNA-based assay for accurate thyroid nodule classification will be presented at the American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress, being held May 12-15, 2015 in Nashville, Tenn.

The data to be presented describes the development of a microRNA-based test that can stratify thyroid lesions as “benign” or “malignant” in preoperative Fine Needle Aspirate (FNA) and in existing cytology smear samples. Following are the details of the poster presentation:

“We look forward to presenting data at this important symposium attended by the leading endocrinologists who diagnose and treat thyroid patients. Interpretation of FNA samples is not always straightforward, which leads to an indeterminate result in up to 30% of the samples. Many patients with indeterminate results are sent to surgery as a precaution, despite the fact the majority of these cases are benign. This exposes patients to unnecessary surgical risk and costs the system hundreds of millions of dollars,” stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

“We believe our novel microRNA-based assay will be highly competitive with current testing methods, which address a total market opportunity of greater than $350 million in the U.S. We look forward to launching our assay in the third quarter of 2015, and expect it will be an effective tool for the accurate diagnosis and classification of thyroid nodules,” added Mr. Berlin.

About Rosetta Cancer Testing Services

Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta’s assays are designed to provide objective diagnostic data. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test™, 62,000 from the Rosetta Kidney Cancer Test™ and 222,000 patients from the Rosetta Lung Cancer Test™. The Company’s assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. In addition to its proprietary products, the Company markets the Rosetta Genomics PGxOne™ and EGFR and KRAS tests for Admera Health. With the recent acquisition of PersonalizeDx, the company now offers a broader menu of molecular and other assays for lung, bladder, prostate and breast cancer patients. For more information, please visit www.rosettagenomics.com. Parties interested in ordering any of these tests can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. PersonalizeDx’s core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology provide additional content and platforms that complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to Rosetta’s development of a microRNA test with the ability to stratify thyroid lesions as “benign” or “malignant” in preoperative Fine Needle Aspirate (FNA) and in existing cytology smear samples (the “Assay”), the Assay being highly competitive with current testing methods, the market opportunity of the Assay, the timing for the launch of the Assay, and the Assay being an effective tool for the accurate diagnosis and classification of thyroid nodules, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.